STOCK TITAN
  1. Home
  2. News
  3. ETNB

89bio Inc - ETNB STOCK NEWS

Welcome to our dedicated news page for 89bio (Ticker: ETNB), a resource for investors and traders seeking the latest updates and insights on 89bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 89bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 89bio's position in the market.

News
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
Rhea-AI Summary
89bio, Inc. appoints Martin Babler, a biotech industry veteran, to its Board of Directors. Babler brings over 30 years of pharmaceutical and biotech experience to the company. His successful track record in building and leading companies through commercialization will be valuable as 89bio progresses with its Phase 3 programs for pegozafermin, a treatment for liver and cardiometabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
management
-
News
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
89bio, Inc. announced the approval of non-qualified stock options for eight new employees under the 2023 Inducement Plan. The options grant a total of 138,550 shares of common stock, with a four-year vesting period. The exercise price matches the closing price on the grant date, following Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
-
News
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
Rhea-AI Summary
89bio, Inc. (ETNB) receives PRIME status from EMA for pegozafermin in MASH patients. Positive data from Phase 2b trial supports the status. Phase 3 trials for non-cirrhotic and cirrhotic patients underway. CEO Rohan Palekar emphasizes pegozafermin's potential in treating MASH patients with advanced fibrosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
none
News
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
Rhea-AI Summary
89bio, Inc. initiates Phase 3 ENLIGHTEN Program for pegozafermin in MASH patients. The program includes two trials, with the first focusing on non-cirrhotic MASH patients with fibrosis stage F2-F3. Co-primary endpoints at week 52 aim to support accelerated approval. The second trial will evaluate patients with compensated cirrhosis. Pegozafermin shows promising anti-fibrotic and metabolic effects, with potential for full approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
clinical trial
-
News
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
89bio, Inc. (ETNB) announces the grant of non-qualified stock options to a new employee as an inducement for joining the company. The grant includes 10,800 shares of common stock, with a four-year vesting period based on continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
-
News
89bio to Participate in the Leerink Partners Global Biopharma Conference
Rhea-AI Summary
89bio, Inc. (ETNB) to participate in Leerink Partners Global Biopharma Conference for investor meetings and fireside chat on March 12, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
conferences
News
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
Rhea-AI Summary
89bio, Inc. (ETNB) plans to initiate Phase 3 trials for NASH patients in 2024, with positive long-term data from Phase 2b trials. The company completed a follow-on offering for $172.5 million, with a strong financial position of $578.9 million in cash and securities by December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.03%
Tags
earnings
-
News
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
89bio, Inc. (ETNB) to present at Oppenheimer 34th Annual Healthcare Life Sciences Conference, showcasing their focus on innovative therapies for liver and cardiometabolic diseases. The webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
conferences
-
News
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
89bio, Inc. announced the approval of non-qualified stock options for two new employees as part of the 2023 Inducement Plan. The options allow the purchase of 28,400 shares of the company's common stock at the closing price on the grant date. The options will vest over a four-year period, subject to the employees' continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.04%
Tags
none
News
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
89bio, Inc. (ETNB) Announces Approval of Non-Qualified Stock Options for New Employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
none
Stock ETNB logo
89bio Inc

Nasdaq:ETNB

ETNB Rankings

#2598 Ranked by Market Cap
#3848 Ranked by Stock Gains
N/A Ranked by Dividends

ETNB Stock Data

918.18M
69.50M
0.86%
106.21%
12.35%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
San Francisco

About ETNB

89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.